126 related articles for article (PubMed ID: 22542492)
1. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders.
Tatara A; Shimizu S; Shin N; Sato M; Sugiuchi T; Imaki J; Ohno Y
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):252-9. PubMed ID: 22542492
[TBL] [Abstract][Full Text] [Related]
2. Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors.
Ohno Y; Imaki J; Mae Y; Takahashi T; Tatara A
Neuropharmacology; 2011; 60(2-3):201-8. PubMed ID: 20813116
[TBL] [Abstract][Full Text] [Related]
3. 5-HT1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms.
Shimizu S; Mizuguchi Y; Tatara A; Kizu T; Andatsu S; Sobue A; Fujiwara M; Morimoto T; Ohno Y
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():86-91. PubMed ID: 23838274
[TBL] [Abstract][Full Text] [Related]
4. Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice.
Shimizu S; Mizuguchi Y; Sobue A; Fujiwara M; Morimoto T; Ohno Y
J Pharmacol Sci; 2015 Apr; 127(4):439-45. PubMed ID: 25850380
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Tada M; Shirakawa K; Matsuoka N; Mutoh S
Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
Ohno Y; Okano M; Imaki J; Tatara A; Okumura T; Shimizu S
Pharmacol Biochem Behav; 2010 Aug; 96(2):175-80. PubMed ID: 20460137
[TBL] [Abstract][Full Text] [Related]
7. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders.
Imaki J; Mae Y; Shimizu S; Ohno Y
Neurosci Lett; 2009 Apr; 454(2):143-7. PubMed ID: 19429072
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic involvement in haloperidol-induced catalepsy.
Neal-Beliveau BS; Joyce JN; Lucki I
J Pharmacol Exp Ther; 1993 Apr; 265(1):207-17. PubMed ID: 8386235
[TBL] [Abstract][Full Text] [Related]
10. Haloperidol-induced catalepsy: a model for screening antidepressants effective in treatment of depression with Parkinson's disease.
Khisti RT; Mandhane SN; Chopde CT
Indian J Exp Biol; 1997 Dec; 35(12):1297-301. PubMed ID: 9567763
[TBL] [Abstract][Full Text] [Related]
11. The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes.
Erosa-Rivero HB; Bata-García JL; Alvarez-Cervera FJ; Heredia-López FJ; Góngora-Alfaro JL
Neuropharmacology; 2014 Jun; 81():176-87. PubMed ID: 24534110
[TBL] [Abstract][Full Text] [Related]
12. Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice.
Arora D; Mudgal J; Nampoothiri M; Mallik SB; Kinra M; Hall S; Anoopkumar-Dukie S; Grant GD; Rao CM
Metab Brain Dis; 2018 Aug; 33(4):1045-1051. PubMed ID: 29516413
[TBL] [Abstract][Full Text] [Related]
13. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
Ohno Y; Shimizu S; Imaki J; Ishihara S; Sofue N; Sasa M; Kawai Y
Neuropharmacology; 2008 Oct; 55(5):717-23. PubMed ID: 18585397
[TBL] [Abstract][Full Text] [Related]
14. Rational polypharmacy in the bipolar affective disorders.
Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M
Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735
[TBL] [Abstract][Full Text] [Related]
15. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M
Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647
[TBL] [Abstract][Full Text] [Related]
16. Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol.
Ali O; Haleem DJ; Saify ZS; Kamil N; Obaid R; Ahmed SW
Pak J Pharm Sci; 2005 Apr; 18(2):23-8. PubMed ID: 16431394
[TBL] [Abstract][Full Text] [Related]
17. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
[TBL] [Abstract][Full Text] [Related]
18. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
Kleven MS; Barret-Grévoz C; Bruins Slot L; Newman-Tancredi A
Neuropharmacology; 2005 Aug; 49(2):135-43. PubMed ID: 15996562
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
20. [Afobazole decreases motor side effects induced by haloperidol].
Seredenin SB; Garibova TA; Kuznetsova AL; Voronin MV; Iarkova MA; Voronina TA
Eksp Klin Farmakol; 2009; 72(1):15-8. PubMed ID: 19334504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
